• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

DNA错配修复基因在接受铂类化疗的卵巢癌患者中的预后价值

Prognostic values of DNA mismatch repair genes in ovarian cancer patients treated with platinum-based chemotherapy.

作者信息

Zhao Chuchu, Li Saisai, Zhao Menghuang, Zhu Haiyan, Zhu Xueqiong

机构信息

Department of Obstetrics and Gynecology, The Second Affiliated Hospital of Wenzhou Medical University, No. 109 Xueyuan Xi Road, Wenzhou, 325027, Zhejiang, China.

出版信息

Arch Gynecol Obstet. 2018 Jan;297(1):153-159. doi: 10.1007/s00404-017-4563-x. Epub 2017 Oct 23.

DOI:10.1007/s00404-017-4563-x
PMID:29063235
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5762798/
Abstract

PURPOSE

DNA mismatch repair (MMR) is a highly conserved biological pathway that plays a key role in maintaining genomic stability. MMR has been reported as a prognostic marker in certain cancers; however, the results are controversial. Therefore, identification of the prognostic value of MMR genes in ovarian cancer based on a large sample size is pivotal.

METHODS

In the current study, we systemically investigated the prognostic roles of seven MMR genes, MSH2, MSH3, MSH6, MLH1, MLH3, PMS1 and PMS2, in ovarian cancer patients treated with platinum-based chemotherapy through "The Kaplan-Meier plotter" (KM plotter) database, which contains gene expression data and survival information of ovarian cancer patients.

RESULTS

Among seven MMR genes, high mRNA levels of MSH6, MLH1 and PMS2 were significantly associated with a better overall survival for all ovarian cancer patients treated with platinum-based chemotherapy, especially in late-stage and poor-differentiated ovarian cancer patients. Increased MSH6 and PMS2 mRNA expression was correlated with a favorable overall survival in serous ovarian cancer patients.

CONCLUSIONS

Our results indicate that sufficient MMR system is associated with an improved survival in ovarian cancer treated with platinum-based chemotherapy. MMR gene may be a potential prognosis predictor in ovarian cancer.

摘要

目的

DNA错配修复（MMR）是一种高度保守的生物学途径，在维持基因组稳定性方面起着关键作用。MMR已被报道为某些癌症的预后标志物；然而，结果存在争议。因此，基于大样本量确定MMR基因在卵巢癌中的预后价值至关重要。

方法

在本研究中，我们通过“The Kaplan-Meier plotter”（KM plotter）数据库系统地研究了7个MMR基因，即MSH2、MSH3、MSH6、MLH1、MLH3、PMS1和PMS2，在接受铂类化疗的卵巢癌患者中的预后作用，该数据库包含卵巢癌患者的基因表达数据和生存信息。

结果

在7个MMR基因中，MSH6、MLH1和PMS2的高mRNA水平与所有接受铂类化疗的卵巢癌患者更好的总生存期显著相关，尤其是在晚期和低分化卵巢癌患者中。MSH6和PMS2 mRNA表达增加与浆液性卵巢癌患者良好的总生存期相关。

结论

我们的结果表明，充足的MMR系统与接受铂类化疗的卵巢癌患者生存率提高相关。MMR基因可能是卵巢癌潜在的预后预测指标。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a9a2/5762798/b45f10caf84c/404_2017_4563_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a9a2/5762798/d64fdf9edede/404_2017_4563_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a9a2/5762798/465c9f9d8c62/404_2017_4563_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a9a2/5762798/b45f10caf84c/404_2017_4563_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a9a2/5762798/d64fdf9edede/404_2017_4563_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a9a2/5762798/465c9f9d8c62/404_2017_4563_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a9a2/5762798/b45f10caf84c/404_2017_4563_Fig3_HTML.jpg

相似文献

1
Prognostic values of DNA mismatch repair genes in ovarian cancer patients treated with platinum-based chemotherapy.DNA错配修复基因在接受铂类化疗的卵巢癌患者中的预后价值
Arch Gynecol Obstet. 2018 Jan;297(1):153-159. doi: 10.1007/s00404-017-4563-x. Epub 2017 Oct 23.
2
Mismatch repair and treatment resistance in ovarian cancer.卵巢癌中的错配修复与治疗耐药性
BMC Cancer. 2006 Jul 31;6:201. doi: 10.1186/1471-2407-6-201.
3
Mismatch repair deficiency in ovarian cancer -- molecular characteristics and clinical implications.卵巢癌中的错配修复缺陷——分子特征与临床意义。
Gynecol Oncol. 2014 Feb;132(2):506-12. doi: 10.1016/j.ygyno.2013.12.003. Epub 2013 Dec 10.
4
Common variants in mismatch repair genes and risk of invasive ovarian cancer.错配修复基因中的常见变异与侵袭性卵巢癌风险
Carcinogenesis. 2006 Nov;27(11):2235-42. doi: 10.1093/carcin/bgl089. Epub 2006 Jun 13.
5
Mismatch repair gene polymorphisms and survival in invasive ovarian cancer patients.错配修复基因多态性与侵袭性卵巢癌患者的生存率
Eur J Cancer. 2008 Oct;44(15):2259-65. doi: 10.1016/j.ejca.2008.07.010. Epub 2008 Aug 22.
6
Up-regulation of mismatch repair genes MSH6, PMS2 and MLH1 parallels development of genetic instability and is linked to tumor aggressiveness and early PSA recurrence in prostate cancer.错配修复基因MSH6、PMS2和MLH1的上调与基因不稳定性的发展并行，且与前列腺癌的肿瘤侵袭性和早期前列腺特异性抗原复发相关。
Carcinogenesis. 2017 Jan;38(1):19-27. doi: 10.1093/carcin/bgw116. Epub 2016 Nov 1.
7
Microsatellite instability and mismatch repair protein defects in ovarian epithelial neoplasms in patients 50 years of age and younger.50岁及以下患者卵巢上皮性肿瘤中的微卫星不稳定性和错配修复蛋白缺陷
Am J Surg Pathol. 2008 Jul;32(7):1029-37. doi: 10.1097/PAS.0b013e31816380c4.
8
MLH1 Is a Prognostic Biomarker for Serous Ovarian Cancer Treated With Platinum- and Taxane-based Chemotherapy.MLH1 是铂类和紫杉烷类化疗治疗的浆液性卵巢癌的预后生物标志物。
Anticancer Res. 2019 Oct;39(10):5505-5513. doi: 10.21873/anticanres.13743.
9
Ovarian endometrioid adenocarcinoma: incidence and clinical significance of the morphologic and immunohistochemical markers of mismatch repair protein defects and tumor microsatellite instability.卵巢子宫内膜样腺癌：错配修复蛋白缺陷和肿瘤微卫星不稳定性的形态和免疫组织化学标志物的发生率和临床意义。
Am J Surg Pathol. 2012 Feb;36(2):163-72. doi: 10.1097/PAS.0b013e31823bc434.
10
[Correlation between mismatch-repair protein expression and clinicopathologic features in 658 colorectal cancers].658例结直肠癌错配修复蛋白表达与临床病理特征的相关性
Zhonghua Bing Li Xue Za Zhi. 2018 Nov 8;47(11):827-833. doi: 10.3760/cma.j.issn.0529-5807.2018.11.003.

引用本文的文献

1
Expression and prognostic significance of MLH1 and GPRC5C in resectable hepatocellular carcinoma.MLH1和GPRC5C在可切除肝细胞癌中的表达及预后意义
BMC Cancer. 2025 Jul 25;25(1):1215. doi: 10.1186/s12885-025-14591-1.
2
RIOK1: A Novel Oncogenic Driver in Hepatocellular Carcinoma.RIOK1：肝细胞癌中的一种新型致癌驱动因子。
Cancer Med. 2025 Feb;14(3):e70597. doi: 10.1002/cam4.70597.
3
Updates in gynecologic care for individuals with lynch syndrome.林奇综合征患者妇科护理的最新进展。

本文引用的文献

1
Up-regulation of mismatch repair genes MSH6, PMS2 and MLH1 parallels development of genetic instability and is linked to tumor aggressiveness and early PSA recurrence in prostate cancer.错配修复基因MSH6、PMS2和MLH1的上调与基因不稳定性的发展并行，且与前列腺癌的肿瘤侵袭性和早期前列腺特异性抗原复发相关。
Carcinogenesis. 2017 Jan;38(1):19-27. doi: 10.1093/carcin/bgw116. Epub 2016 Nov 1.
2
Mismatch repair system proteins in oral benign and malignant lesions.
J Oral Pathol Med. 2017 Apr;46(4):241-245. doi: 10.1111/jop.12484. Epub 2016 Aug 10.
3
Long-term survival of patients with mismatch repair protein-deficient, high-stage ovarian clear cell carcinoma.错配修复蛋白缺陷的晚期卵巢透明细胞癌患者的长期生存情况。
Front Oncol. 2023 Mar 1;13:1127683. doi: 10.3389/fonc.2023.1127683. eCollection 2023.
4
Complex molecular profile of DNA repair genes in epithelial ovarian carcinoma patients with different sensitivity to platinum-based therapy.对铂类疗法敏感性不同的上皮性卵巢癌患者DNA修复基因的复杂分子特征
Front Oncol. 2022 Dec 2;12:1016958. doi: 10.3389/fonc.2022.1016958. eCollection 2022.
5
Mismatch repair markers in preoperative and operative endometrial cancer samples; expression concordance and prognostic value.术前和手术子宫内膜癌样本中的错配修复标志物；表达一致性和预后价值。
Br J Cancer. 2023 Feb;128(4):647-655. doi: 10.1038/s41416-022-02063-3. Epub 2022 Dec 8.
6
BRCA Mutations in Ovarian and Prostate Cancer: Bench to Bedside.卵巢癌和前列腺癌中的BRCA突变：从 bench 到 bedside。 （注：bench 到 bedside 可理解为从基础研究到临床应用，这里直接保留英文以便更准确传达原文语境）
Cancers (Basel). 2022 Aug 11;14(16):3888. doi: 10.3390/cancers14163888.
7
DNA Damage Repair: Predictor of Platinum Efficacy in Ovarian Cancer?DNA损伤修复：卵巢癌铂类疗效的预测指标？
Biomedicines. 2021 Dec 31;10(1):82. doi: 10.3390/biomedicines10010082.
8
Extensive three-dimensional intratumor proteomic heterogeneity revealed by multiregion sampling in high-grade serous ovarian tumor specimens.通过对高级别浆液性卵巢肿瘤标本进行多区域采样揭示的广泛三维肿瘤内蛋白质组异质性
iScience. 2021 Jun 21;24(7):102757. doi: 10.1016/j.isci.2021.102757. eCollection 2021 Jul 23.
9
A multidisciplinary approach remains the best strategy to improve and strengthen the management of ovarian cancer (Review).多学科方法仍然是改善和加强卵巢癌管理的最佳策略（综述）。
Int J Oncol. 2021 Jul;59(1). doi: 10.3892/ijo.2021.5233. Epub 2021 Jun 16.
10
Sequence Neighborhoods Enable Reliable Prediction of Pathogenic Mutations in Cancer Genomes.序列邻域有助于可靠预测癌症基因组中的致病突变。
Cancers (Basel). 2021 May 14;13(10):2366. doi: 10.3390/cancers13102366.
Histopathology. 2017 Jan;70(2):309-313. doi: 10.1111/his.13040. Epub 2016 Sep 21.
4
Frequent mismatch-repair defects link prostate cancer to Lynch syndrome.频繁的错配修复缺陷将前列腺癌与林奇综合征联系起来。
BMC Urol. 2016 Mar 24;16:15. doi: 10.1186/s12894-016-0130-1.
5
Mismatch Repair and Colon Cancer: Mechanisms and Therapies Explored.错配修复与结肠癌：机制与治疗探索。
Trends Mol Med. 2016 Apr;22(4):274-289. doi: 10.1016/j.molmed.2016.02.003. Epub 2016 Mar 9.
6
Polymorphisms in mismatch repair genes are associated with risk and microsatellite instability of gastric cancer, and interact with life exposures.错配修复基因多态性与胃癌风险及微卫星不稳定性相关，并与生活暴露因素相互作用。
Gene. 2016 Mar 15;579(1):52-7. doi: 10.1016/j.gene.2015.12.050. Epub 2015 Dec 24.
7
PSMB4 expression associates with epithelial ovarian cancer growth and poor prognosis.蛋白酶体亚基β型4（PSMB4）的表达与上皮性卵巢癌的生长及不良预后相关。
Arch Gynecol Obstet. 2016 Jun;293(6):1297-307. doi: 10.1007/s00404-015-3904-x. Epub 2015 Oct 6.
8
PMS2 expression in epithelial ovarian cancer is posttranslationally regulated by Akt and essential for platinum-induced apoptosis.PMS2在卵巢上皮癌中的表达受Akt蛋白翻译后调控，且对铂诱导的细胞凋亡至关重要。
Tumour Biol. 2016 Mar;37(3):3059-69. doi: 10.1007/s13277-015-4143-2. Epub 2015 Sep 30.
9
Deficient mismatch repair: Read all about it (Review).错配修复缺陷：全面了解（综述）。
Int J Oncol. 2015 Oct;47(4):1189-202. doi: 10.3892/ijo.2015.3119. Epub 2015 Aug 12.
10
Primary debulking surgery vs. neoadjuvant chemotherapy followed by interval debulking surgery for patients with advanced ovarian cancer.初次肿瘤细胞减灭术与新辅助化疗后间隔肿瘤细胞减灭术治疗晚期卵巢癌的疗效比较。
Arch Gynecol Obstet. 2016 Jan;293(1):163-168. doi: 10.1007/s00404-015-3813-z. Epub 2015 Jul 22.